ApoB cholesterol study published
Analysis based on 10 articles · First reported Jul 06, 2026 · Last updated Jul 08, 2026
The findings could shift clinical practice toward broader use of apoB testing, potentially increasing demand for such tests and benefiting diagnostic companies. However, the impact is gradual and unlikely to cause immediate market moves.
A study from Northwestern University published in JAMA in April 2026 found that measuring apolipoprotein B (apoB) is more effective than standard LDL or non-HDL cholesterol tests for identifying patients who need intensive cholesterol-lowering therapy to prevent heart attacks and strokes. The research, led by Ciaran Kohli-Lynch, used a computer simulation of 250,000 U.S. adults and showed that an apoB-guided strategy improved health outcomes and was cost-effective. The American Heart Association and American College of Cardiology have issued updated guidelines emphasizing earlier and more personalized cholesterol management. The study was supported by an American Heart Association Career Development Award.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard